Cancer Capital (CNCL) 10-K 15 Apr 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-32363
Entity Registrant Name	CANCER CAPITAL CORP.
Entity Central Index Key	0001130889
Entity Tax Identification Number	91-1803648
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	440 East 400 South
Entity Address, Address Line Two	Ste 300
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84111
City Area Code	(801)
Local Phone Number	323-2395
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Public Float				$ 0
Entity Common Stock, Shares Outstanding			6,150,000
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	5525	6117
Auditor Name	Fruci & Associates II, PLLC	Pinnacle Accountancy Group of Utah
Auditor Location	Spokane, Washington	Farmington, Utah

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 16,157	$ 22,055
Total current assets	16,157	22,055
Total assets	16,157	22,055
CURRENT LIABILITIES
Accounts payable - related party	6,000	6,000
Notes payable – related party	164,125	155,125
Notes payable	130,275	130,275
Accrued interest – related party	90,153	77,680
Accrued interest	74,996	64,574
Total current liabilities	465,549	433,654
Total liabilities	465,549	433,654
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding	6,150	6,150
Additional paid-in capital	47,050	47,050
Accumulated deficit	(502,592)	(464,799)
Total stockholders' deficit	(449,392)	(411,599)
Total liabilities and stockholders' deficit	$ 16,157	$ 22,055

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	20,000,000	20,000,000
Common Stock, Shares, Issued	6,150,000	6,150,000
Common Stock, Shares, Outstanding	6,150,000	6,150,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues
Operating Expenses
General and administrative	14,897	21,008
Total operating expenses	14,897	21,008
Loss from operations	(14,897)	(21,008)
Other income (expense)
Interest expense – related party	(12,473)	(11,729)
Interest expense	(10,422)	(9,730)
Total other income (expense)	(22,895)	(21,459)
Loss before income taxes	(37,792)	(42,467)
Income tax expense
Net loss	$ (37,792)	$ (42,467)
Net loss per share – basic and diluted	$ (0.01)	$ (0.01)
Weighted average shares outstanding – basic and diluted	6,150,000	6,150,000

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance – December 31, 2021 at Dec. 31, 2021	$ 6,150	$ 47,050	$ (422,332)	$ (369,132)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	6,150,000
Net loss			(42,467)	(42,467)
Balance – December 31, 2022 at Dec. 31, 2022	$ 6,150	47,050	(464,799)	(411,599)
Shares, Outstanding, Ending Balance at Dec. 31, 2022	6,150,000
Net loss			(37,792)	(37,792)
Balance – December 31, 2022 at Dec. 31, 2023				(449,392)
Shares, Outstanding, Ending Balance at Dec. 31, 2023	6,150,000
Balance – December 31, 2023 at Dec. 31, 2023	$ 6,150	$ 47,050	$ (502,591)	$ (449,391)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net Loss	$ (37,792)	$ (42,467)
Adjustment to reconcile net loss to cash used by operating activities:
Expenses paid by related party	6,000	6,000
Changes in operating assets and liabilities:
Decrease in accounts payable
Increase in accrued interest – related party	12,473	11,729
Increase in accrued interest	10,422	9,730
Net cash used by operating activities	(8,897)	(15,008)
Cash Flows from Investing Activities
Net cash provided by investing activities
Cash Flows from Financing Activities
Proceeds from notes payable		33,000
Proceeds from notes payable – related party	3,000	4,000
Net cash provided by financing activities	3,000	37,000
Increase (decrease) in cash	(5,897)	21,993
Cash and cash equivalents at beginning of year	22,054	62
Cash and cash equivalents at end of year	16,157	22,055
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities
Conversion of related party accounts payable into notes payable – related party	$ 6,000	$ 6,000

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Organization & Summary of Significant Accounting Policies Cancer Capital Corp. (the Company), was incorporated April 11, 1997 under the laws of the State of Nevada. The Company was originally formed for the purpose of developing an alternative medical waste treatment system. However, the Company, in December 1997, minimized this purpose and since that time its efforts have been directed more to raising capital, development of the Company’s business plan, SEC filings and other limited operations. b. Loss Per Share The computation of earnings per share of Common Stock is based on the weighted average number of shares outstanding at the date of the financial statements. There are no potentially dilutive Common Stock equivalents. For the Years Ended 2023 2022 Net Loss $ (37,792 ) $ (42,467 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 ) c. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. d. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. e. Concentrations of Risk As of December 31, 2023, two lenders represent in excess of 95 f. Recent Accounting Pronouncements The Company has evaluated Recent Accounting Pronouncements and has determined that tall such pronouncements either do not apply or their impact is insignificant to the financial statements. g. Fair Value Measurements If required by authoritative literature, the Company would account for certain assets and liabilities at fair value. The cash, accounts payable, notes payable and accrued interest have fair values that approximate their carrying values due to the short-term nature of these instruments.

NOTE 2 - INCOME TAXES

NOTE 2 - INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
NOTE 2 - INCOME TAXES	NOTE 2 - INCOME TAXES The Company follows ASC 740-10 which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company currently has no issues creating timing differences that would mandate deferred tax expense. Net operating losses would create possible tax assets in future years. Due to the uncertainty of the utilization of net operating loss carry forwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. A provision for income taxes has not been made due to net operating loss carry-forwards of $ 502,592 464,799 Deferred tax assets and the valuation account are as follows: For the Years Ended 2023 2022 Deferred tax asset: Net operating loss carryforward (at 21%) $ 105,544 $ 97,608 Valuation allowance (105,544 ) (97,608 ) $ — $ — A reconciliation of amounts obtained by applying the Federal tax rate to pre-tax income to income tax benefit is as follows: For the Years Ended 2023 2022 Federal tax benefit (at 21%) $ 7,936 $ 8,918 Change in valuation allowance (7,936 ) (8,918 ) Effect of rate change on Deferred Tax Asset — — $ — $ — The Company did not have any tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions. The tax years that remain subject to examination by major taxing jurisdictions are those for the years ended December 31, 2023, 2022, 2021, and 2020.

NOTE 3 - GOING CONCERN

NOTE 3 - GOING CONCERN	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 3 - GOING CONCERN	NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has a negative working capital of $ 449,392 502,592

NOTE 4 - NOTES PAYABLE

NOTE 4 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
NOTE 4 - NOTES PAYABLE	NOTE 4 - NOTES PAYABLE Notes payable as of December 31, 2023 and 2022 were $ 130,275 130,275 8 0 33,000 Accrued interest for the notes payable was $ 74,996 64,574

NOTE 5 - RELATED PARTY TRANSACT

NOTE 5 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
NOTE 5 - RELATED PARTY TRANSACTIONS	NOTE 5 - RELATED PARTY TRANSACTIONS As of the years ended December 31, 2023 and 2022, the Company incurred $ 6,000 6,000 6,000 6,000 164,125 155,125 90,153 77,680 8

NOTE 6 _ STOCKHOLDERS_ EQUITY

NOTE 6 – STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
NOTE 6 – STOCKHOLDERS’ EQUITY	NOTE 6 – STOCKHOLDERS’ EQUITY There was no stock issued during 2023 and 2022.

NOTE 7 _ SUBSEQUENT EVENTS

NOTE 7 – SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
NOTE 7 – SUBSEQUENT EVENTS	NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

NOTE 1 - SUMMARY OF SIGNIFICA_2

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
a. Organization & Summary of Significant Accounting Policies	a. Organization & Summary of Significant Accounting Policies Cancer Capital Corp. (the Company), was incorporated April 11, 1997 under the laws of the State of Nevada. The Company was originally formed for the purpose of developing an alternative medical waste treatment system. However, the Company, in December 1997, minimized this purpose and since that time its efforts have been directed more to raising capital, development of the Company’s business plan, SEC filings and other limited operations.
b. Loss Per Share	b. Loss Per Share The computation of earnings per share of Common Stock is based on the weighted average number of shares outstanding at the date of the financial statements. There are no potentially dilutive Common Stock equivalents. For the Years Ended 2023 2022 Net Loss $ (37,792 ) $ (42,467 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 )
c. Cash and Cash Equivalents	c. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents.
d. Use of estimates	d. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
e. Concentrations of Risk	e. Concentrations of Risk As of December 31, 2023, two lenders represent in excess of 95
f. Recent Accounting Pronouncements	f. Recent Accounting Pronouncements The Company has evaluated Recent Accounting Pronouncements and has determined that tall such pronouncements either do not apply or their impact is insignificant to the financial statements.
g. Fair Value Measurements	g. Fair Value Measurements If required by authoritative literature, the Company would account for certain assets and liabilities at fair value. The cash, accounts payable, notes payable and accrued interest have fair values that approximate their carrying values due to the short-term nature of these instruments.

NOTE 1 - SUMMARY OF SIGNIFICA_3

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]	For the Years Ended 2023 2022 Net Loss $ (37,792 ) $ (42,467 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 )

NOTE 2 - INCOME TAXES (Tables)

NOTE 2 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Summary of Valuation Allowance [Table Text Block]	For the Years Ended 2023 2022 Deferred tax asset: Net operating loss carryforward (at 21%) $ 105,544 $ 97,608 Valuation allowance (105,544 ) (97,608 ) $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the Years Ended 2023 2022 Federal tax benefit (at 21%) $ 7,936 $ 8,918 Change in valuation allowance (7,936 ) (8,918 ) Effect of rate change on Deferred Tax Asset — — $ — $ —

Computation of earnings per sha

Computation of earnings per share of common stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Net Loss	$ (37,792)	$ (42,467)
Weighted Average Number of Shares Outstanding	6,150,000	6,150,000
Basic Loss per Common Share	$ (0.01)	$ (0.01)

NOTE 1 - SUMMARY OF SIGNIFICA_4

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Concentration Risk, Percentage	95%

Deferred tax assets and the val

Deferred tax assets and the valuation account (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforward (at 21%)	$ 105,544	$ 97,608
Valuation allowance	$ (105,544)	$ (97,608)

Reconciliation of federal incom

Reconciliation of federal income tax rates (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal tax benefit (at 21%)	$ 7,936	$ 8,918
Change in valuation allowance	(7,936)	(8,918)
Effect of rate change on Deferred Tax Asset

NOTE 2 - INCOME TAXES (Details

NOTE 2 - INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 502,592	$ 464,799

NOTE 3 - GOING CONCERN (Details

NOTE 3 - GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Banking Regulation, Total Capital, Actual	$ (449,392)
Retained Earnings (Accumulated Deficit)	$ (502,592)	$ (464,799)

NOTE 4 - NOTES PAYABLE (Details

NOTE 4 - NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes Payable, Current	$ 130,275	$ 130,275
Debt Instrument, Interest Rate During Period	8%	8%
Proceeds from Notes Payable		$ 33,000
Interest Payable, Current	$ 74,996	$ 64,574

NOTE 5 - RELATED PARTY TRANSA_2

NOTE 5 - RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Costs and Expenses, Related Party	$ 6,000	$ 6,000
[custom:ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty]	6,000	6,000
[custom:NotesPayableRelatedPartiesClassifiedCurrent1-0]	164,125	155,125
Accrued Liabilities and Other Liabilities	$ 90,153	$ 77,680
Debt Instrument, Interest Rate During Period	8%	8%